Mumps and measles virus immunogens and their use
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human Services
InventorsBarney Graham, Guillaume Stewart-Jones, Rebecca J. Loomis
Life of this patent
Estimating the term…
Abstract
Embodiments of immunogens comprising a recombinant Mumps (MuV) F ectodomain trimer stabilized in a prefusion conformation or a recombinant Measles (MeV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also provided are embodiments of immunogens comprising chimeric proteins comprising the recombinant MuV or MeV F ectodomain trimer and one or more MuV HN or MeV H ectodomains. Also disclosed are nucleic acids encoding the immunogens and methods of their production. Methods for inducing an immune response in a subject by administering a disclosed immunogen to the subject are also provided. In some embodiments, the immune response treats or inhibits MuV and/or MeV infection in a subject.
Claims35
An immunogen, comprising:
- a recombinant Mumps virus (MuV) F ectodomain trimer stabilized in a prefusion conformation by one or more amino acid substitutions in protomers of the trimer, the amino acid substitutions comprising cysteine substitutions that form a non-natural disulfide bond to stabilize the MuV Fectodomain trimer in the prefusion conformation, wherein the cysteine substitutions are located at one or more of MuV F positions 86 and 215, positions 155 and 161, positions 165 and 231, positions 206 and 223, positions 209 and 214, and positions 221 and 255, according to a reference MuV F amino acid sequence set forth as SEQ ID NO:
- 1.
Dependencies are inferred from the claim text.